massimaux | 15 points | Nov 14 2020 12:08:07

Link: https://www.researchsquare.com/article/rs-100956/v1

Study design:  A multicenter randomized controlled clinical trial (RCCT) study design was carried out on on 600 subjects; 400 patients and 200 health care and household contacts at Benha and Kafrelsheikh University Hospitals.

Study setting: Benha and Kafrelsheikh University Hospitals (COVID-19 Isolation Hospitals).

Study period: The study was carried out from 8th June to 15th September 2020.  

*Study population (Sampling Design and Sample Size):

The study was conducted on 600 subjects; 400 patients and 200 health care and household contacts that were divided into 6 groups:

4 treatment groups: 2 with IVM+SoC and 2 with HCQ+SoC

Group I: 100 patients with Mild/Moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care;

Group II: 100 patients with mild/moderate COVID-19 infection received hydroxyxholorquine plus standard of care;

Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standard of care;

Group IV: 100 patients with Severe COVID-19 infection received hydroxyxholorquine plus standard of care. Routine laboratory investigations and RT-PCR were reported before and after initiation of treatment.

2 prophylaxis groups: IVM+PPE and PPE only

Group V stick to personal protective equipment (PPE) plus Ivermectin 400mcg / kg to be repeated after one week, and

Group VI stick to PPE only and both groups V&VI were followed for two weeks.

​

Results:

Table (4) shows that there was a highly statistically significant improvement associated with significant reduction in mortality in groups received Ivermectin & (groups I & III) compared to those received Hydroxychloroquine (p-value \<0.001).

Table (5): showed that Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group

permalink